GW Gets Two Cannabis-Based Meds Backed By NICE
Epidyolex And Sativex Recommended
Two cannabis-based drugs developed by GW Pharmaceuticals have been approved for use on the NHS in England for the first time and will be prescribed to patients with epilepsy and multiple sclerosis.
You may also be interested in...
The easing of the regulations governing GW Pharmaceuticals’ groundbreaking epilepsy drug in the UK will be followed by wider availability in Europe as pricing and reimbursement discussions continue.
GW Pharmaceuticals is pressing on with plans to launch its epilepsy treatment Epidyolex in the EU, starting with France and Germany.
Draft guidance from NICE has recommended against the use of GW Pharmaceuticals’ Epidyolex for refractory epilepsy, but the company believes it has the data needed to ensure a positive outcome to the appraisal.